首页 > 最新文献

Recent Advances in Inflammation & Allergy Drug Discovery最新文献

英文 中文
Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes. 抗cd3抗体和抗cd20抗体:治疗和预防1型糖尿病的免疫治疗策略综述
IF 0.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/2772270817666221122103029
Prajakta Kashalikar, Shivani Desai, Avinash Sanap, Madhura Shekatkar, Ramesh Bhonde

Background and objective: Type 1 diabetes mellitus is a complex disease defined by the loss of pancreatic cells, which leads to complete insulin insufficiency. The Diabetes Control and Problems Trial defines the aims of Type 1 diabetes therapy as achieving adequate glycaemic control, and preventing and avoiding recurrent bouts of hypoglycaemia. Despite ongoing efforts to improve insulin therapy regimens, the actual hormone substitute therapy treats just the symptoms of the disease, with no influence on disease pathology or etiopathogenesis. In recent decades, there has been a lot of interest in preventative techniques in high-risk patients, based on the theory that if a therapeutic intervention is adopted early in the disease, it can help maintain endogenous cell function by protecting the remaining cell reservoir from autoimmune attack.

Methods: Based on preclinical and clinical data, we have discussed some immunotherapeutic in this meta-analysis. We referred to the preclinical and clinical studies for teplizumab and rituximab from authentic databases and compiled the data. We used statistical analysis to do a meta-analysis.

Results: In two immunotherapeutic anti-CD3 antibodies and anti-CD20 antibodies examples, teplizumab and rituximab, respectively, shows better efficacy as well as fewer side effects. We have discussed this drug briefly based on their mechanism of action and meta-analysis, which compare clinical efficacy.

Conclusion: Immunotherapeutic can be a better option for preventing and protecting type one diabetes. Since, the existing literature does not have enough data to support any single drug concluding the same will not be appropriate. Hence further studies are required wherein different drugs can be compared with similar sample sizes for each group of drugs.

背景与目的:1型糖尿病是一种复杂的疾病,其特征是胰腺细胞损失,导致胰岛素完全不足。糖尿病控制和问题试验将1型糖尿病治疗的目标定义为达到适当的血糖控制,预防和避免低血糖复发。尽管正在努力改善胰岛素治疗方案,但实际的激素替代疗法只是治疗疾病的症状,对疾病病理或发病机制没有影响。近几十年来,人们对高危患者的预防技术产生了很大的兴趣,基于这样一种理论,即如果在疾病早期采取治疗干预,它可以通过保护剩余的细胞库免受自身免疫攻击来帮助维持内源性细胞功能。方法:基于临床前和临床数据,我们在此荟萃分析中讨论了一些免疫治疗方法。我们参考了来自真实数据库的teplizumab和rituximab的临床前和临床研究,并汇编了数据。我们用统计分析做了荟萃分析。结果:在两个免疫治疗性抗cd3抗体和抗cd20抗体的例子中,teplizumab和rituximab分别表现出更好的疗效和更少的副作用。我们根据两种药物的作用机制和meta分析对其临床疗效进行了简要的讨论。结论:免疫治疗是预防和保护1型糖尿病的较好选择。因为,现有文献没有足够的数据来支持任何一种药物得出相同的结论是不合适的。因此,需要进一步的研究,其中不同的药物可以比较相似的样本量的每组药物。
{"title":"Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes.","authors":"Prajakta Kashalikar,&nbsp;Shivani Desai,&nbsp;Avinash Sanap,&nbsp;Madhura Shekatkar,&nbsp;Ramesh Bhonde","doi":"10.2174/2772270817666221122103029","DOIUrl":"https://doi.org/10.2174/2772270817666221122103029","url":null,"abstract":"<p><strong>Background and objective: </strong>Type 1 diabetes mellitus is a complex disease defined by the loss of pancreatic cells, which leads to complete insulin insufficiency. The Diabetes Control and Problems Trial defines the aims of Type 1 diabetes therapy as achieving adequate glycaemic control, and preventing and avoiding recurrent bouts of hypoglycaemia. Despite ongoing efforts to improve insulin therapy regimens, the actual hormone substitute therapy treats just the symptoms of the disease, with no influence on disease pathology or etiopathogenesis. In recent decades, there has been a lot of interest in preventative techniques in high-risk patients, based on the theory that if a therapeutic intervention is adopted early in the disease, it can help maintain endogenous cell function by protecting the remaining cell reservoir from autoimmune attack.</p><p><strong>Methods: </strong>Based on preclinical and clinical data, we have discussed some immunotherapeutic in this meta-analysis. We referred to the preclinical and clinical studies for teplizumab and rituximab from authentic databases and compiled the data. We used statistical analysis to do a meta-analysis.</p><p><strong>Results: </strong>In two immunotherapeutic anti-CD3 antibodies and anti-CD20 antibodies examples, teplizumab and rituximab, respectively, shows better efficacy as well as fewer side effects. We have discussed this drug briefly based on their mechanism of action and meta-analysis, which compare clinical efficacy.</p><p><strong>Conclusion: </strong>Immunotherapeutic can be a better option for preventing and protecting type one diabetes. Since, the existing literature does not have enough data to support any single drug concluding the same will not be appropriate. Hence further studies are required wherein different drugs can be compared with similar sample sizes for each group of drugs.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"17 1","pages":"64-70"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9933851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-arthritic and Antioxidant Effects of Trehalose in an Experimental Model of Arthritis. 海藻糖在关节炎实验模型中的抗关节炎和抗氧化作用。
IF 0.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230825093141
Fatemeh Forouzanfar, Mohammad Moein Vakilzadeh, Ali Mehri, Ali Mohammad Pourbagher-Shahri, Shiva Ganjali, Mitra Abbasifard, Amirhossein Sahebkar

Background: The purpose of the present study was to study the potential anti-arthritic and antioxidant effects of trehalose in an experimental model of complete Freund's adjuvant (CFA)-induced arthritis.

Methods: Arthritis was induced via subcutaneous injection of CFA (0.1) into the right footpad of each rat. Trehalose (10 mg/kg per day) and indomethacin (5 mg/kg) as a reference drug were intraperitoneally injected into CFA-induced arthritic rats from days 0 to 21. Changes in paw volume, pain responses, arthritic score, and oxidative/antioxidative parameters were determined.

Results: Trehalose administration could significantly decrease arthritis scores (p <0.01) and paw edema (p <0.001), and significantly increase the nociceptive threshold (p <0.05) in CFA-induced arthritic rats. Trehalose also significantly reduced the pro-oxidant-antioxidant balance values when compared to CFA treatment alone. In addition, no significant difference was found between the trehalose group and indomethacin as a positive control group.

Conclusion: The current study suggests that trehalose has a protective effect against arthritis, which may be mediated by antioxidative effects of this disaccharide.

背景:本研究的目的是研究海藻糖在完全弗氏佐剂(CFA)诱导的关节炎实验模型中的潜在抗关节炎和抗氧化作用。方法:大鼠右足皮下注射CFA(0.1)诱导关节炎。从第0 ~ 21天腹腔注射海藻糖(10 mg/kg / d)和吲哚美辛(5 mg/kg)作为参比药物。测定足爪体积、疼痛反应、关节炎评分和氧化/抗氧化参数的变化。结果:海藻糖可显著降低关节炎评分(p)。结论:本研究提示海藻糖对关节炎具有保护作用,其机制可能与海藻糖的抗氧化作用有关。
{"title":"Anti-arthritic and Antioxidant Effects of Trehalose in an Experimental Model of Arthritis.","authors":"Fatemeh Forouzanfar, Mohammad Moein Vakilzadeh, Ali Mehri, Ali Mohammad Pourbagher-Shahri, Shiva Ganjali, Mitra Abbasifard, Amirhossein Sahebkar","doi":"10.2174/2772270817666230825093141","DOIUrl":"10.2174/2772270817666230825093141","url":null,"abstract":"<p><strong>Background: </strong>The purpose of the present study was to study the potential anti-arthritic and antioxidant effects of trehalose in an experimental model of complete Freund's adjuvant (CFA)-induced arthritis.</p><p><strong>Methods: </strong>Arthritis was induced via subcutaneous injection of CFA (0.1) into the right footpad of each rat. Trehalose (10 mg/kg per day) and indomethacin (5 mg/kg) as a reference drug were intraperitoneally injected into CFA-induced arthritic rats from days 0 to 21. Changes in paw volume, pain responses, arthritic score, and oxidative/antioxidative parameters were determined.</p><p><strong>Results: </strong>Trehalose administration could significantly decrease arthritis scores (p <0.01) and paw edema (p <0.001), and significantly increase the nociceptive threshold (p <0.05) in CFA-induced arthritic rats. Trehalose also significantly reduced the pro-oxidant-antioxidant balance values when compared to CFA treatment alone. In addition, no significant difference was found between the trehalose group and indomethacin as a positive control group.</p><p><strong>Conclusion: </strong>The current study suggests that trehalose has a protective effect against arthritis, which may be mediated by antioxidative effects of this disaccharide.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"145-151"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10444484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between Cardiac Atrioventricular Conduction and Antibodies to Chlamydia Pneumoniae in Fibromyalgia Patients. 纤维肌痛患者心脏房室传导与肺炎衣原体抗体的关系
IF 0.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230705140935
Basant K Puri, Georgia Tuckey, Lucy Cowans, Gary S Lee, Armin Schwarzbach

Background: Fibromyalgia patients may complain of cardiovascular symptoms, including chest pain and palpitations. It has been proposed that infection by Chlamydia pneumoniae might be common in fibromyalgia. Chlamydia pneumoniae infection has also been hypothesized to be a causative factor in cardiac disease.

Objective: This study aims to test the hypothesis that there is an association between atrioventricular conduction and antibodies to Chlamydia pneumoniae in fibromyalgia.

Methods: Thirteen female fibromyalgia patients underwent serum Chlamydia pneumoniae IgG assays and 12-lead electrocardiography in a cross-sectional study. None of the patients was taking medication which might affect atrioventricular conduction, and none suffered from hypothyroidism, renal disease, hepatic disease, or carotid hypersensitivity.

Results: There was a significant positive correlation between the PR interval duration and the serum Chlamydia pneumoniae IgG level (r = 0.650; p = 0.016).

Conclusion: This study supports the hypothesis of an association between atrioventricular conduction and antibodies to Chlamydia pneumoniae in fibromyalgia patients. It suggests that the higher the level of such antibodies, the greater the electrocardiographic PR interval, and therefore the slower the atrioventricular conduction. Potential pathophysiological mechanisms include a chronic inflammatory response to Chlamydia pneumoniae and the action of the bacterial lipopolysaccharide. The latter may involve stimulators of interferon genes, activation of the cardiac NOD-like receptor protein 3 inflammasomes, and downregulation of fibroblast growth factor 5 in the heart.

背景:纤维肌痛患者可能主诉心血管症状,包括胸痛和心悸。有人提出,肺炎衣原体感染可能是常见的纤维肌痛。肺炎衣原体感染也被假设为心脏病的一个致病因素。目的:本研究旨在验证纤维肌痛患者房室传导与肺炎衣原体抗体相关的假说。方法:对13例女性纤维肌痛患者进行了血清肺炎衣原体IgG检测和12导联心电图横断面研究。所有患者均未服用影响房室传导的药物,无甲状腺功能减退、肾脏疾病、肝脏疾病或颈动脉过敏。结果:PR间隔时间与血清肺炎衣原体IgG水平呈显著正相关(r = 0.650;P = 0.016)。结论:本研究支持纤维肌痛患者房室传导与肺炎衣原体抗体相关的假设。提示此类抗体水平越高,心电图PR间期越长,因此房室传导越慢。潜在的病理生理机制包括对肺炎衣原体的慢性炎症反应和细菌脂多糖的作用。后者可能涉及干扰素基因的刺激、心脏nod样受体蛋白3炎症小体的激活和心脏成纤维细胞生长因子5的下调。
{"title":"Association between Cardiac Atrioventricular Conduction and Antibodies to <i>Chlamydia Pneumoniae</i> in Fibromyalgia Patients.","authors":"Basant K Puri, Georgia Tuckey, Lucy Cowans, Gary S Lee, Armin Schwarzbach","doi":"10.2174/2772270817666230705140935","DOIUrl":"10.2174/2772270817666230705140935","url":null,"abstract":"<p><strong>Background: </strong>Fibromyalgia patients may complain of cardiovascular symptoms, including chest pain and palpitations. It has been proposed that infection by <i>Chlamydia pneumoniae</i> might be common in fibromyalgia. <i>Chlamydia pneumoniae</i> infection has also been hypothesized to be a causative factor in cardiac disease.</p><p><strong>Objective: </strong>This study aims to test the hypothesis that there is an association between atrioventricular conduction and antibodies to <i>Chlamydia pneumoniae</i> in fibromyalgia.</p><p><strong>Methods: </strong>Thirteen female fibromyalgia patients underwent serum <i>Chlamydia pneumoniae</i> IgG assays and 12-lead electrocardiography in a cross-sectional study. None of the patients was taking medication which might affect atrioventricular conduction, and none suffered from hypothyroidism, renal disease, hepatic disease, or carotid hypersensitivity.</p><p><strong>Results: </strong>There was a significant positive correlation between the PR interval duration and the serum <i>Chlamydia pneumoniae</i> IgG level (<i>r </i>= 0.650; <i>p</i> = 0.016).</p><p><strong>Conclusion: </strong>This study supports the hypothesis of an association between atrioventricular conduction and antibodies to <i>Chlamydia pneumoniae</i> in fibromyalgia patients. It suggests that the higher the level of such antibodies, the greater the electrocardiographic PR interval, and therefore the slower the atrioventricular conduction. Potential pathophysiological mechanisms include a chronic inflammatory response to <i>Chlamydia pneumoniae</i> and the action of the bacterial lipopolysaccharide. The latter may involve stimulators of interferon genes, activation of the cardiac NOD-like receptor protein 3 inflammasomes, and downregulation of fibroblast growth factor 5 in the heart.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"127-132"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9746392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vivo Analgesic Activity of New N-arylphthalimides Derivatives in Mice. 新型n -芳基邻苯二胺衍生物在小鼠体内的镇痛活性。
IF 0.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230302145537
Asghar Davood, Atefeh Saadabadi, Porya Torkaman, Ehsan Salehi, Hamed Shafaroodi

Background: A series of phthalimides related to thalidomide have been studied for analgesic activity in the formalin test. The formalin test was performed in mice in a nociceptive pattern to evaluate analgesic activity.

Methods: In this study, nine derivatives of phthalimides were evaluated in terms of exerting analgesic effects in mice. They exerted significant analgesic effects compared to indomethacin and negative control. These compounds were synthesized and characterized by TLC, followed by IR and H1NMR in the previous studies. Two distinct periods of high licking activity were used to analyze both acute and chronic pain. All compounds were compared with indomethacin and carbamazepine as positive control and vehicle as a negative control.

Results: All of the tested compounds exhibited significant analgesic activity in both the first and second phases of the test compared to the control group (DMSO), although they did not show more activity than the reference drug (indomethacin) but were comparable to indomethacin.

Conclusion: This information may be useful in the development of a more potent phthalimide as an analgesic agent that acts as a sodium channel blocker and COX inhibitor.

背景:研究了一系列与沙利度胺相关的邻苯二胺在福尔马林试验中的镇痛活性。在小鼠中进行福尔马林试验,以评估痛觉模式的镇痛活性。方法:对9种邻苯二甲酸亚胺衍生物的小鼠镇痛作用进行了研究。与吲哚美辛和阴性对照相比,它们具有显著的镇痛效果。这些化合物在之前的研究中已经合成并通过TLC、IR和H1NMR进行了表征。两个不同时期的高舔活动被用来分析急性和慢性疼痛。所有化合物与吲哚美辛和卡马西平为阳性对照,对照物为阴性对照。结果:与对照组(DMSO)相比,所有被测化合物在试验的第一和第二阶段都表现出显著的镇痛活性,尽管它们没有表现出比参比药物(吲哚美辛)更强的活性,但与吲哚美辛相当。结论:这些信息可能有助于开发更有效的邻苯二胺作为钠通道阻滞剂和COX抑制剂的镇痛剂。
{"title":"<i>In vivo</i> Analgesic Activity of New N-arylphthalimides Derivatives in Mice.","authors":"Asghar Davood, Atefeh Saadabadi, Porya Torkaman, Ehsan Salehi, Hamed Shafaroodi","doi":"10.2174/2772270817666230302145537","DOIUrl":"10.2174/2772270817666230302145537","url":null,"abstract":"<p><strong>Background: </strong>A series of phthalimides related to thalidomide have been studied for analgesic activity in the formalin test. The formalin test was performed in mice in a nociceptive pattern to evaluate analgesic activity.</p><p><strong>Methods: </strong>In this study, nine derivatives of phthalimides were evaluated in terms of exerting analgesic effects in mice. They exerted significant analgesic effects compared to indomethacin and negative control. These compounds were synthesized and characterized by TLC, followed by IR and H<sup>1</sup>NMR in the previous studies. Two distinct periods of high licking activity were used to analyze both acute and chronic pain. All compounds were compared with indomethacin and carbamazepine as positive control and vehicle as a negative control.</p><p><strong>Results: </strong>All of the tested compounds exhibited significant analgesic activity in both the first and second phases of the test compared to the control group (DMSO), although they did not show more activity than the reference drug (indomethacin) but were comparable to indomethacin.</p><p><strong>Conclusion: </strong>This information may be useful in the development of a more potent phthalimide as an analgesic agent that acts as a sodium channel blocker and COX inhibitor.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"121-126"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9380191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Complex Regional Pain Syndrome (CRPS): New Perspectives in the use of Sulfonamides as Modulators of P2X Receptors. 复杂局部疼痛综合征(CRPS)的治疗:磺胺类药物作为P2X受体调节剂的新视角
IF 0.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230320124000
Giulia Culletta, Anna Maria Almerico, Marco Tutone
{"title":"Treatment of Complex Regional Pain Syndrome (CRPS): New Perspectives in the use of Sulfonamides as Modulators of P2X Receptors.","authors":"Giulia Culletta, Anna Maria Almerico, Marco Tutone","doi":"10.2174/2772270817666230320124000","DOIUrl":"10.2174/2772270817666230320124000","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"88-95"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9221418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structural Insights to the Pathophysiology of Effector Induced Immunostimulation in Salmonella Typhimurium: Biocomputational Methods. 鼠伤寒沙门菌效应诱导免疫刺激的病理生理结构:生物计算方法。
IF 0.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230515125053
Abhigyan Choudhury

Introduction: The worldwide impact of the foodborne pathogen Salmonella can never be overstated, nor can be the fatal threat of septicemia in patients infected with its Typhimurium serovar. Behind the hyperimmune response in the case of septicemia lies a critical phenomenon of the bacterial pathogenic signals being sensed by different pattern recognition receptors, such as the Typhimurium effector proteins that are detected by toll-like receptors.

Methods: To mitigate such a threat, precise structural and functional description of these effectors is necessary. The same has been addressed in this article using accelerated biocomputational techniques, beginning with the identification of the functional niche of the effectors and their influence over other proteins.

Results: The molecular crystal structures were retrieved, and rigorous molecular docking experiments were conducted among the TLRs and effector proteins in order to examine the interactions. The interactions were thereby evaluated and screened according to their respective strengths using parameters including binding affinity, dissociation constant, hydropathy variation, etc. SopB effectors were found to be detected by three different TLR proteins and GtgE by two other TLRs, while SifA, SrfJ, and SsaV had only a single interacting TLR partner each. Interestingly, TLR9 presented lower sensitivity towards PAMPs of this bacterium.

Conclusion: Normal modal analyses in combination with atomistic molecular dynamics simulations that tend to imitate natural cytosolic environments reveal stable and consistent interactions and realistic conformations among the effector-bound TLR complexes. The findings open up new avenues for the development of targeted therapies against Salmonella, which could significantly reduce the global burden of this foodborne pathogen.

食源性病原体沙门氏菌的全球影响永远不能被夸大,也不能是致命的威胁,败血症的患者感染了它的鼠伤寒杆菌血清型。在败血症病例的超免疫反应背后是细菌致病信号被不同模式识别受体感知的一个关键现象,例如鼠伤寒效应蛋白被toll样受体检测到。方法:为了减轻这种威胁,有必要对这些效应物进行精确的结构和功能描述。本文使用加速生物计算技术解决了同样的问题,从确定效应物的功能生态位及其对其他蛋白质的影响开始。结果:获得了分子晶体结构,并在tlr与效应蛋白之间进行了严格的分子对接实验,以考察其相互作用。通过结合亲和度、解离常数、亲水变化等参数,对相互作用进行了评价和筛选。SopB效应物被三种不同的TLR蛋白检测到,而GtgE被另外两种TLR检测到,而SifA、SrfJ和SsaV各自只有一个相互作用的TLR伴侣。有趣的是,TLR9对该细菌的PAMPs表现出较低的敏感性。结论:正态模态分析与原子分子动力学模拟相结合,倾向于模仿自然细胞质环境,揭示了效应结合的TLR复合物之间稳定一致的相互作用和真实的构象。这一发现为开发针对沙门氏菌的靶向治疗开辟了新的途径,可以显著减轻这种食源性病原体的全球负担。
{"title":"Structural Insights to the Pathophysiology of Effector Induced Immunostimulation in <i>Salmonella Typhimurium</i>: Biocomputational Methods.","authors":"Abhigyan Choudhury","doi":"10.2174/2772270817666230515125053","DOIUrl":"10.2174/2772270817666230515125053","url":null,"abstract":"<p><strong>Introduction: </strong>The worldwide impact of the foodborne pathogen <i>Salmonella</i> can never be overstated, nor can be the fatal threat of septicemia in patients infected with its <i> Typhimurium</i> serovar. Behind the hyperimmune response in the case of septicemia lies a critical phenomenon of the bacterial pathogenic signals being sensed by different pattern recognition receptors, such as the <i>Typhimurium</i> effector proteins that are detected by toll-like receptors.</p><p><strong>Methods: </strong>To mitigate such a threat, precise structural and functional description of these effectors is necessary. The same has been addressed in this article using accelerated biocomputational techniques, beginning with the identification of the functional niche of the effectors and their influence over other proteins.</p><p><strong>Results: </strong>The molecular crystal structures were retrieved, and rigorous molecular docking experiments were conducted among the TLRs and effector proteins in order to examine the interactions. The interactions were thereby evaluated and screened according to their respective strengths using parameters including binding affinity, dissociation constant, hydropathy variation, <i>etc</i>. SopB effectors were found to be detected by three different TLR proteins and GtgE by two other TLRs, while SifA, SrfJ, and SsaV had only a single interacting TLR partner each. Interestingly, TLR9 presented lower sensitivity towards PAMPs of this bacterium.</p><p><strong>Conclusion: </strong>Normal modal analyses in combination with atomistic molecular dynamics simulations that tend to imitate natural cytosolic environments reveal stable and consistent interactions and realistic conformations among the effector-bound TLR complexes. The findings open up new avenues for the development of targeted therapies against <i>Salmonella</i>, which could significantly reduce the global burden of this foodborne pathogen.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"133-144"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9475017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aeroallergen-specific Immunotherapy and Biologics Co-administration: Cost-benefit Re-considerations are Urgently Needed. 空气过敏原特异性免疫治疗和生物制剂联合给药:迫切需要重新考虑成本效益。
IF 0.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230320153734
George N Konstantinou, Maria Petrodimopoulou
{"title":"Aeroallergen-specific Immunotherapy and Biologics Co-administration: Cost-benefit Re-considerations are Urgently Needed.","authors":"George N Konstantinou, Maria Petrodimopoulou","doi":"10.2174/2772270817666230320153734","DOIUrl":"10.2174/2772270817666230320153734","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"85-87"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9878951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nano-Phytopharmaceuticals in Inflammation. 炎症中的纳米植物药物。
IF 0.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230123121836
Akhila S, Remya K

Inflammation is a defense mechanism of the body against harmful stimuli/organisms. Even if it is the body's defense mechanism, these mediators may affect different ways in the human body and can lead to chronic disorders. The most common treatment strategy for the acute type of inflammation mainly includes synthetic chemical drugs; Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressant drugs whereas these synthetic drugs have many side effects, adverse effects, and limitations. Herbal drugs can be a promising alternative to these synthetic drugs but they too have limitations. Recent advances in the nanotechnology field can be combined with herbal drugs to overcome the limitations. Research works done on topical nanophyto pharmaceuticals for anti-inflammatory activity were compiled and in all the studies, clear evidence is indicated for the increased penetration, distribution, and increased efficacy of phytopharmaceuticals when formulated into nano dosage forms. Considering the adverse effects and limitations of most widely used synthetic drugs, topical nano Phyto pharmaceuticals can play a pivotal role in the local and systemic delivery of promising phytoconstituents to a specific site of the body.

炎症是机体对抗有害刺激/生物体的一种防御机制。即使是人体的防御机制,这些介质也可能以不同的方式影响人体,并可能导致慢性疾病。急性型炎症最常用的治疗策略主要包括合成化学药物;非甾体抗炎药(NSAIDs),皮质类固醇和免疫抑制药物而这些合成药物有许多副作用,副作用和局限性。草药可能是这些合成药物的一个有希望的替代品,但它们也有局限性。纳米技术领域的最新进展可以与草药相结合来克服这些局限性。对局部纳米植物药物抗炎活性的研究工作进行了汇编,在所有研究中,明确的证据表明,当制成纳米剂型时,植物药物的渗透、分布和功效都有所增加。考虑到大多数广泛使用的合成药物的副作用和局限性,局部纳米植物药物可以在将有希望的植物成分局部和全身递送到身体特定部位方面发挥关键作用。
{"title":"Nano-Phytopharmaceuticals in Inflammation.","authors":"Akhila S,&nbsp;Remya K","doi":"10.2174/2772270817666230123121836","DOIUrl":"https://doi.org/10.2174/2772270817666230123121836","url":null,"abstract":"<p><p>Inflammation is a defense mechanism of the body against harmful stimuli/organisms. Even if it is the body's defense mechanism, these mediators may affect different ways in the human body and can lead to chronic disorders. The most common treatment strategy for the acute type of inflammation mainly includes synthetic chemical drugs; Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressant drugs whereas these synthetic drugs have many side effects, adverse effects, and limitations. Herbal drugs can be a promising alternative to these synthetic drugs but they too have limitations. Recent advances in the nanotechnology field can be combined with herbal drugs to overcome the limitations. Research works done on topical nanophyto pharmaceuticals for anti-inflammatory activity were compiled and in all the studies, clear evidence is indicated for the increased penetration, distribution, and increased efficacy of phytopharmaceuticals when formulated into nano dosage forms. Considering the adverse effects and limitations of most widely used synthetic drugs, topical nano Phyto pharmaceuticals can play a pivotal role in the local and systemic delivery of promising phytoconstituents to a specific site of the body.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"17 1","pages":"31-38"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9933882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Prognostic Role of Corticosteroid Administration in Hospitalized Patients with Severe COVID-19: A Cross-sectional Study. 皮质类固醇在重症新冠肺炎住院患者中的预后作用:一项跨部门研究。
IF 0.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/0127722708245041230921064257
Mohammad Ali Yaghoubi, Hassan Mehrad-Majd, Ali Moradi, Mohammad Moein Vakilzadeh, Zahra Mazloum Khorasani, Mahmoud Ghavi, Amirhossein Sahebkar

Background and objective: The COVID-19 pandemic is a recent global issue with no established consensus on treatments. Therefore, the aim of this study was to assess the impact of corticosteroid (CS) pulses on the prognosis of COVID-19 patients admitted to hospitals.

Methods: In this retrospective single-center cross-sectional study, we used hospital records of all consecutive patients aged 18 years or older admitted to the hospital from July 23rd to September 23rd, 2021. All patients included in the study had confirmed SARS-CoV-2 infection using polymerase chain reaction (PCR) testing and required hospitalization. Demographic and clinical information, as well as patient outcomes, were collected. Treatment details, including the type(s), cumulative doses, and duration of administered corticosteroids, were also recorded. CS pulse therapy was defined as the daily administration of 24 mg or more of dexamethasone or its equivalents.

Results: A total of 500 patients with COVID-19 were included in this study, comprising 122 patients who received CS pulse therapy and 378 patients who did not. A higher mortality rate was observed in patients receiving CS pulse therapy (42.6%) compared to the other group (28%) (p =0.04). Additionally, logistic regression analysis showed an increased mortality risk in patients receiving CS pulse therapy in the crude model (OR=1.54, 95% CI: 1.01-2.27, p <0.01). However, after adjusting for confounding factors, such as mechanical ventilation and ICU admission, the results were reversed (OR=0.21, 95% CI: 0.07-0.62, p <0.01). ; Conclusion: In the findings of the current study, treatment with CS pulses was shown to significantly enhance recovery in patients with non-severe COVID-19.

背景和目的:新冠肺炎大流行是最近的一个全球性问题,在治疗方面尚未达成共识。因此,本研究的目的是评估皮质类固醇(CS)脉冲对住院新冠肺炎患者预后的影响。方法:在这项回顾性单中心横断面研究中,我们使用了2021年7月23日至9月23日收治的所有连续18岁或以上患者的医院记录。研究中的所有患者都已通过聚合酶链式反应(PCR)检测确认感染了严重急性呼吸系统综合征冠状病毒2型,需要住院治疗。收集人口统计学和临床信息以及患者结果。还记录了治疗细节,包括皮质类固醇的类型、累积剂量和持续时间。CS脉冲治疗定义为每天给予24mg或更多地塞米松或其等效物。结果:共有500名新冠肺炎患者被纳入本研究,其中122名患者接受了CS脉冲治疗,378名患者未接受CS脉冲治疗。接受CS脉冲治疗的患者的死亡率(42.6%)高于另一组(28%)(p=0.04),逻辑回归分析显示,在粗模型中,接受CS脉冲治疗的患者的死亡率风险增加(OR=1.54,95%CI:1.01-2.27,p结论:在当前研究的结果中,CS脉冲治疗可显著提高非严重新冠肺炎患者的恢复。
{"title":"The Prognostic Role of Corticosteroid Administration in Hospitalized Patients with Severe COVID-19: A Cross-sectional Study.","authors":"Mohammad Ali Yaghoubi, Hassan Mehrad-Majd, Ali Moradi, Mohammad Moein Vakilzadeh, Zahra Mazloum Khorasani, Mahmoud Ghavi, Amirhossein Sahebkar","doi":"10.2174/0127722708245041230921064257","DOIUrl":"10.2174/0127722708245041230921064257","url":null,"abstract":"<p><strong>Background and objective: </strong>The COVID-19 pandemic is a recent global issue with no established consensus on treatments. Therefore, the aim of this study was to assess the impact of corticosteroid (CS) pulses on the prognosis of COVID-19 patients admitted to hospitals.</p><p><strong>Methods: </strong>In this retrospective single-center cross-sectional study, we used hospital records of all consecutive patients aged 18 years or older admitted to the hospital from July 23rd to September 23rd, 2021. All patients included in the study had confirmed SARS-CoV-2 infection using polymerase chain reaction (PCR) testing and required hospitalization. Demographic and clinical information, as well as patient outcomes, were collected. Treatment details, including the type(s), cumulative doses, and duration of administered corticosteroids, were also recorded. CS pulse therapy was defined as the daily administration of 24 mg or more of dexamethasone or its equivalents.</p><p><strong>Results: </strong>A total of 500 patients with COVID-19 were included in this study, comprising 122 patients who received CS pulse therapy and 378 patients who did not. A higher mortality rate was observed in patients receiving CS pulse therapy (42.6%) compared to the other group (28%) (p =0.04). Additionally, logistic regression analysis showed an increased mortality risk in patients receiving CS pulse therapy in the crude model (OR=1.54, 95% CI: 1.01-2.27, p <0.01). However, after adjusting for confounding factors, such as mechanical ventilation and ICU admission, the results were reversed (OR=0.21, 95% CI: 0.07-0.62, p <0.01). ; Conclusion: In the findings of the current study, treatment with CS pulses was shown to significantly enhance recovery in patients with non-severe COVID-19.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"152-157"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49683028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 Associated Pancytopenia (CAP): A Clinical Impact. COVID-19相关性全血细胞减少症(CAP):临床影响
IF 0.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/2772270817666221207094122
Jitendra Singh, Anju Dinkar, Nilesh Kumar, Kailash Kumar

Background: SARS-CoV-2 infection has mild and asymptomatic to critical clinical course affecting mainly the lungs. Few case reports of COVID-19-associated pancytopenia are reported, but a series of 18 cases is not described in the literature to date.

Aims and objectives: This study aimed to investigate pancytopenia in COVID-19 and its correlation with severity and to explore the detailed clinical and biochemical information in COVID-19- associated pancytopenia. This study also highlights pancytopenia's rarity and prognostic value among COVID-19 patients.

Materials and methods: This was a retrospective observational study conducted in a tertiary care centre at a level 3 COVID care facility that included adults of either sex having positive RT PCR for COVID-19 from October 2020 to May 2021. Data were collected from the online outpatient department and hospitalized patients.

Results: A total of 18 cases were included in the study; 13 were males (72.2%). The mean age was calculated as 48.56 years. Cases were categorized as severe 13 (72.2%) and non-severe 5 (27.8%) disease on the first day of pancytopenia. The most common presentations were fever 18 (100%) and cough 18 (100%), followed by generalized weakness 16 (88.9%), breathlessness 15 (83.3%), and diarrhoea 10 (55.6%). One case died in the severe disease group. The mean of haemoglobin, leukocyte count, and platelets in severe vs non-severe disease were calculated as 8.59 vs 8.74, 2339 vs 2578, and 77769 vs 88600, respectively.

Conclusion: Pancytopenia was more prevalent in severe disease and age group 40-60 years. CAP was most likely due to secondary bone marrow suppression. It has no prognostic value for disease outcomes.

背景:SARS-CoV-2感染的临床过程为轻、无症状至危重期,主要累及肺部。很少有与covid -19相关的全血细胞减少症的病例报告,但迄今为止,文献中没有描述一系列18例病例。目的:本研究旨在探讨COVID-19全血细胞减少症及其与严重程度的相关性,并探讨COVID-19相关全血细胞减少症的详细临床和生化信息。该研究还强调了全血细胞减少症在COVID-19患者中的罕见性和预后价值。材料和方法:这是一项回顾性观察性研究,在一家三级COVID-19护理机构的三级护理中心进行,研究对象包括2020年10月至2021年5月期间RT - PCR检测为COVID-19阳性的男女成年人。数据收集自在线门诊和住院患者。结果:共纳入18例;男性13例(72.2%)。平均年龄为48.56岁。在全血细胞减少的第一天,病例分为重度13例(72.2%)和非重度5例(27.8%)。最常见的症状是发热(100%)和咳嗽(100%),其次是全身无力(88.9%)、呼吸困难(83.3%)和腹泻(55.6%)。重症组1例死亡。重症与非重症患者血红蛋白、白细胞计数和血小板的平均值分别为8.59 vs 8.74、2339 vs 2578和77769 vs 88600。结论:全血细胞减少症以重症和40 ~ 60岁年龄组多见。CAP最有可能是继发性骨髓抑制所致。它对疾病结局没有预后价值。
{"title":"COVID-19 Associated Pancytopenia (CAP): A Clinical Impact.","authors":"Jitendra Singh,&nbsp;Anju Dinkar,&nbsp;Nilesh Kumar,&nbsp;Kailash Kumar","doi":"10.2174/2772270817666221207094122","DOIUrl":"https://doi.org/10.2174/2772270817666221207094122","url":null,"abstract":"<p><strong>Background: </strong>SARS-CoV-2 infection has mild and asymptomatic to critical clinical course affecting mainly the lungs. Few case reports of COVID-19-associated pancytopenia are reported, but a series of 18 cases is not described in the literature to date.</p><p><strong>Aims and objectives: </strong>This study aimed to investigate pancytopenia in COVID-19 and its correlation with severity and to explore the detailed clinical and biochemical information in COVID-19- associated pancytopenia. This study also highlights pancytopenia's rarity and prognostic value among COVID-19 patients.</p><p><strong>Materials and methods: </strong>This was a retrospective observational study conducted in a tertiary care centre at a level 3 COVID care facility that included adults of either sex having positive RT PCR for COVID-19 from October 2020 to May 2021. Data were collected from the online outpatient department and hospitalized patients.</p><p><strong>Results: </strong>A total of 18 cases were included in the study; 13 were males (72.2%). The mean age was calculated as 48.56 years. Cases were categorized as severe 13 (72.2%) and non-severe 5 (27.8%) disease on the first day of pancytopenia. The most common presentations were fever 18 (100%) and cough 18 (100%), followed by generalized weakness 16 (88.9%), breathlessness 15 (83.3%), and diarrhoea 10 (55.6%). One case died in the severe disease group. The mean of haemoglobin, leukocyte count, and platelets in severe vs non-severe disease were calculated as 8.59 vs 8.74, 2339 vs 2578, and 77769 vs 88600, respectively.</p><p><strong>Conclusion: </strong>Pancytopenia was more prevalent in severe disease and age group 40-60 years. CAP was most likely due to secondary bone marrow suppression. It has no prognostic value for disease outcomes.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"17 1","pages":"71-78"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9876411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Recent Advances in Inflammation & Allergy Drug Discovery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1